Corient Private Wealth LP Purchases New Position in Twist Bioscience Corporation $TWST

Corient Private Wealth LP bought a new position in Twist Bioscience Corporation (NASDAQ:TWST) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 21,636 shares of the company’s stock, valued at approximately $2,226,000.

Other hedge funds also recently modified their holdings of the company. ARK Investment Management LLC boosted its holdings in Twist Bioscience by 12.4% in the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after purchasing an additional 832,687 shares in the last quarter. William Blair Investment Management LLC raised its holdings in Twist Bioscience by 43.7% during the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock valued at $188,874,000 after buying an additional 1,812,146 shares in the last quarter. BlackRock Inc. bought a new position in Twist Bioscience during the second quarter valued at about $600,191,000. EdgePoint Investment Group Inc. lifted its position in shares of Twist Bioscience by 31.7% in the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock worth $170,590,000 after buying an additional 1,295,672 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Twist Bioscience by 17.4% in the fourth quarter. State Street Corp now owns 3,627,818 shares of the company’s stock worth $115,074,000 after buying an additional 538,755 shares during the last quarter.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Canaccord Genuity Group increased their price objective on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. UBS Group set a $89.00 price objective on Twist Bioscience in a research note on Monday, June 15th. Piper Sandler boosted their target price on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Guggenheim reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 24th. Finally, Evercore downgraded Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target on the stock. in a report on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.30.

Insider Buying and Selling

In other Twist Bioscience news, CEO Emily M. Leproust sold 113,318 shares of Twist Bioscience stock in a transaction on Monday, August 10th. The stock was sold at an average price of $125.16, for a total value of $14,182,880.88. Following the completion of the transaction, the chief executive officer owned 818,938 shares in the company, valued at approximately $102,498,280.08. The trade was a 12.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 2,399 shares of the company’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the transaction, the chief financial officer owned 110,276 shares in the company, valued at approximately $10,402,335.08. This trade represents a 2.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 193,099 shares of company stock valued at $24,026,581 in the last ninety days. Insiders own 3.08% of the company’s stock.

Twist Bioscience Stock Down 0.8%

TWST stock opened at $131.00 on Thursday. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $155.44. The company has a market cap of $8.22 billion, a PE ratio of -59.01 and a beta of 2.22. The business’s 50-day simple moving average is $109.76 and its 200 day simple moving average is $75.81. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. During the same quarter in the previous year, the company posted $0.33 earnings per share. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.